Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (835)	11/20/1998 2:13:00 PM
From: Biomaven	Read Replies (1) of 965

I exited my holding at the opening this morning. The reports of adverse reactions in retreated Crohns patients are probably just a reflection of an impurity in the original formulation (see the ISIS thread for details), but with a stock like CNTO that has a large short position this sort of news tends to be magnified. There appear to be no such reactions in re-treated RA patients, either because they are using the newer formulation or because the patients are on methotrexate. Thus I'm going to wait on the sidelines for a while, watching for a re-entry point. Peer

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next